Terminé

A Preliminary Study of Prophylactic Fentanyl Pectin Nasal Spray (FPNS) for Exercise-Induced Breakthrough Dyspnea

0 critères remplis à partir de votre profilVoyez en un coup d'œil comment votre profil répond à chaque critère d'éligibilité.
Ce qui est testé

Fentanyl Pectin Nasal Spray

+ Walk Test

+ Questionnaires

MédicamentAutreComportemental
Qui peut participer

Troubles respiratoires+3

+ Maladies des voies respiratoires

+ Signes et symptômes

À partir de 18 ans
+18 critères d'éligibilité
Voir tous les critères d'éligibilité
Comment se déroule l'étude

Soins de support

Groupe PlaceboPhase 2
Interventionnel
Date de début : juin 2013
Voir le détail du protocole

Résumé

Sponsor principalM.D. Anderson Cancer Center
Dernière mise à jour : 8 juin 2023
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Date de début de l'étude : 11 juin 2013

Date à laquelle le premier participant a commencé l'étude.

Study Groups: If you are found to be eligible to take part in this study, you will be randomly assigned (as in the flip of a coin) to receive either fentanyl or placebo. You will have an equal chance of being assigned to either group. Neither you nor the study staff will know to which group you have been assigned. However, if needed for your safety, the study staff will be able to find out what you are receiving. Study Drug/Placebo Administration: Before you receive the study drug/placebo, you will walk back and forth in an indoor hallway for up to 6 minutes. You may feel out of breath or become exhausted. You may slow down, stop, and rest at any time you need to. After that, you will sit down and rest (for about 30 minutes). You will then be given the study drug/placebo by a nasal spray. You will then wait for another 20 minutes and repeat the walking test. After that, you will sit down and rest (for about 30 minutes). You will then be given the study drug/placebo again by a nasal spray. You will then wait for another 20 minutes and repeat the walking test for a third time. Study Visit: During your study visit, the study staff will collect information from your medical record about your age, sex, race, disease type, your performance status, any drugs you are taking, and possible causes of shortness of breath. Before each walk test, you will complete the questionnaires about your symptoms. Before and after each walk test, the study staff will record your heart rate, breathing rate, and the level of oxygen in your blood using a measuring device that will be clipped onto your finger. The study staff will also ask you 3 questions about how hard it is to catch your breath and your level of tiredness. During each walk test, you will be asked 6 times how hard it is to catch your breath. The distance you walked and how often and for how long you stopped will be recorded. Before and after the second and third walk tests, the study staff will ask you about any side effects from the study drug/placebo that you may be having. During the rest period between the walk tests, you may be asked several times how hard it is to catch your breath. After each walk test, you will also be asked to complete 4 tests of your mental abilities, including finger tapping, simple mathematics questions (addition, subtraction, multiplication, division), recall of numbers, and recall of objects. It should take 15 minutes to complete these tests. At the end of the study visit, you will complete 1 questionnaire that asks if you think the study drug/placebo is helping you, and how satisfied you are with the study. It should take about 5 minutes to complete the questionnaire. Length of Study: You will be on this study for up to 3 hours. You will be taken off study if intolerable side effects occur during the study. This is an investigational study. Fentanyl is FDA approved and commercially available for the treatment of pain. Its use to help with shortness of breath is investigational. Up to 25 patients will be enrolled in this study. All will be enrolled at MD Anderson.

NCT01832402
Sponsor principalM.D. Anderson Cancer Center
Dernière mise à jour : 8 juin 2023
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Protocole

Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.
Détails du design

35 participants à inclure

Nombre total de participants que l'essai clinique vise à recruter.

Soins de support

Cette étude teste des approches visant à améliorer le confort, le bien-être ou la qualité de vie des personnes atteintes d'une maladie, notamment en aidant à mieux gérer les symptômes.



Éligibilité

Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.
Conditions
Critères

Tout sexe

Le sexe biologique des participants éligibles à s'inscrire.

À partir de 18 ans

Tranche d'âge des participants éligibles à participer.

Volontaires sains non autorisés

Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.

Conditions

Pathologie

Troubles respiratoiresMaladies des voies respiratoiresSignes et symptômesSignes et symptômes, RespiratoiresConditions pathologiques, signes et symptômesDyspnée

Critères

8 critères d'inclusion nécessaires pour participer
Able to complete study assessments

Age 18 or older

Ambulatory and able to walk with or without walking aid

Breakthrough dyspnea, defined in this study as dyspnea on exertion with an average intensity level >= 3/10 on the numeric rating scale

Voir plus de critères

10 critères d'exclusion empêchent la participation
Delirium (i.e. Memorial delirium rating scale > 13)

Dyspnea at rest >= 7/10 at the time of enrollment

History of active opioid abuse within the past 12 months

History of allergy to fentanyl

Voir plus de critères

Plan de l'étude

Découvrez tous les traitements administrés dans cette étude, leur description détaillée et ce qu'ils impliquent.
Groupes de traitement
Objectifs de l'étude

2 groupes d'intervention sont désignés dans cette étude

50% de chances d'être dans le groupe placebo en aveugle

Groupes de traitement

Groupe I

Expérimental
Fentanyl pectin nasal (FPNS) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD). FPNS administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test. Walk test administered before first dose of FPNS. Participant will rest for 30 minutes after walk test. FPNS administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. FPNS administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes. Questionnaires completed at baseline, before each walk test, and at end of final walk test. Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.

Groupe II

Placebo
Placebo nasal spray administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test. Walk test administered before first dose of placebo nasal spray. Participant will rest for 30 minutes after walk test. Placebo nasal spray administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. Placebo nasal spray administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes. Questionnaires completed at baseline, before each walk test, and at end of final walk test. Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.

Objectifs de l'étude

Objectifs principaux

Objectifs secondaires

Centres d'étude

Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.

Cette étude comporte 1 site

University of Texas MD Anderson Cancer Center

Houston, United StatesOuvrir University of Texas MD Anderson Cancer Center dans Google Maps
Terminé1 Centres d'Étude